Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Winter Steven Mark"'
Autor:
Winter Steven Mark, Joan A. Keiser, David Austen Perry, Eileen R. Blasi, Michael J. DePasquale, William T. Loging, Delvin R. Knight, Gregory W Cadelina
Publikováno v:
Drug Development Research. 70:35-48
ILLUMINATE, the Phase 3 clinical trial of morbidity and mortality (MM PF-868,348 is weakly potent and CP-746,281 and CE-308,958 are CETP-inactive. Changes in blood pressure were determined in conscious animals in conjunction with pharmacologic blocka
Autor:
Joan A. Keiser, Mike Engwall, Mark Bamberger, Allison Betts, Robert Wolk, Winter Steven Mark, Eileen R. Blasi, D. R. Knight, Annette John-Baptiste
Publikováno v:
Journal of cardiovascular pharmacology. 53(6)
ILLUMINATE, the phase 3 morbidity and mortality trial of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, plus atorvastatin terminated in 2006. The underlying morbidity and mortality cause remains undetermined. In addition to lip
Autor:
Kevin Coleman, Richard S. Finn, Sherry L. Ralston, Erling Emerson, Connell Richard D, Jitesh P. Jani, Mary Campbell, Leslie R. Pustilnik, Nicolas Currier, Larry Wagner, Ann Marie Rossi, Samit Kumar Bhattacharya, Stefanus J. Steyn, Eugenia Floyd, Kristina Rafidi, John Charles Kath, Winter Steven Mark, Joel Morris, Shawn Harriman, James D. Moyer
Publikováno v:
Cancer research. 67(20)
Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach. It has been implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of
Publikováno v:
Pharmaceutical Biotechnology ISBN: 9780306457432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::083ebca00aeddcdcacd1462239f56639
https://doi.org/10.1007/0-306-47384-4_20
https://doi.org/10.1007/0-306-47384-4_20